SPECIFICITY OF ANTI-TRNA SYNTHETASE AUTOANTIBODIES CORRELATED WITH CLINICAL COURSE AND PROGNOSIS OF MYOSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE

Yoichi Isehara, Yasushi Kondo, Yoko Nakagome, Kazuki Hirano, Yasushi Koyama, Sosuke Sasaki, Katayoshi Kurihara, Yuto Izumi, Chihyo Yamada, Shinji Sato, Tokai University School of Medicine, Division of Rheumatology, Department of Internal Medicine, Isehara-shi, Japan

Background: Interstitial lung disease (ILD) is associated with mortality among patients with idiopathic inflammatory myopathy (IIM). Anti-aminoacyl-RNA synthetase (anti-ARS) autoantibodies have been identified highly specific for IIM and coincident of ILD. It has been identified that non-Jo-1 positive anti-ARS patients may have decreased survival rate. However, differences of characteristics and prognosis in myositis-associated ILD with an individual anti-ARS autoantibody have not been clarified.

Objectives: To compare the characteristics and cumulative survival of myositis-associated ILD with different positivity of anti-ARS antibodies.

Methods: We investigated retrospectively all consecutive patients with myositis-associated ILD evaluated from 1999-2017. All autoantibodies were screened by using RNA and protein immunoprecipitation assays. Demographic data, laboratory findings and chest computed tomography (CT) images were obtained.

Results: Among 105 patients with myositis-associated ILD, enrolled, 47 had anti-Jo-1 antibody and 58 had non-Jo-1 antibody: anti-PL7 (n=20), anti-PL12 (n=12), anti-KS (n=6) and anti-OJ (n=7). The diagnosis at first visit were polymyositis (PM; n=28), dermatomyositis (DM; n=42), clinically amyopathic dermatomyositis (CADM; n=3) and antisynthetase syndrome (ASS; n=31). Most common causes of death in this study were exacerbation of ILD (n=10), 71.4%. Anti-Jo-1 positive patients had better ILD prognosis than non-Jo-1 patients (log rank test, p = 0.03). The prevalence of rapid progression ILD (RP-ILD) and upper lung field lesions in CT scans were significantly higher in anti-Jo-1 positive patients (p=0.02 and p=0.05, respectively). Although the prognosis of ILD was not significantly different among 6 anti-ARS antibodies, anti-EOJ positive patients had poor ILD prognosis than anti-Jo1 patients with the 5-year cumulative survival rate was 73% and 95%, respectively.

Conclusion: Our data confirms that the characteristics and outcomes of myositis-associated ILD are distinct by anti-ARS antibodies and highlighted that anti-Jo-1 antibody positivity with relatively poor prognosis and RP-ILD.

REFERENCES

Acknowledgement: The authors would particularly like to thank Etsuko Iwata and Masui for their assistance.

Disclosure of Interests: None declared.


ASSOCIATION OF ANTI-RNA POLYMERASE III ANTIBODY AND BREAST IMPLANTS RUPTURE IN ITALIAN PATIENTS WITH SYSTEMIC SCLEROSIS

Maria Grazia Lazzaroni,1,2 Cristiano Caimmì,2 Eugenia Bertoldo,2 Franco Franceschini,2 Angela Tincani, Paolo Alì1.2.3.4.5

1. ASST Spedali Civili and University of Brescia, Rheumatology and Clinical Immunology, Brescia, Italy; 2. University of Brescia, Molecular and Translational Medicine Department, Brescia, Italy; 3. Azienda Ospedaliero Universitaria Integrata, Rheumatology Unit, Verona, Italy

Background: Several epidemiological studies have investigated the link between silicone breast implants (SBI) and Systemic Sclerosis (SSc). Although discordant data were reported, a recent analysis of SBI followed by United States Food and Drug Administration post approval studies, including nearly 100,000 individuals, described an association of SBI with a higher rate of SSc (Standardized incidence ratio 7.00), compared with non-users.1 The analysis of clinical associations in patients with SSc is complicated by the heterogeneity of the disease, both on immunological and clinical terms. Interestingly, a specific association of anti-RNA polymerase III antibody (anti-RNAP3) and SBI in Japanese patients with SSc was described in a single-center cohort. Moreover, an association of anti-RNAP3 with breast cancer, particularly when synchronous with SSc onset, was also demonstrated.2-4

Objectives: To evaluate the association of SBI with SSc in Italian patients classified according to their SSc-related autoantibodies.

Methods: 562 consecutive women with SSc, classified according the 2013 ACR/EULAR criteria, were evaluated for the presence of SSc-specific autoantibodies (anti-Topoisomerase I (anti-Topo-I), anticentromere (ACA), and anti-RNAP3) in two Italian University centres. For each patient, history of breast cancer and SBI were recorded.

Results: Anti-RNAP3 antibodies were found in 4.6%, anti-Topo-I in 22.2% and ACA in 57.3% of total SSc women (Table 1). Comparing anti-RNAP3+ vs anti-RNAP3- patients, a significantly higher frequency of breast cancer (15.3% vs 4.1%; p=0.026), SBI (11.5% vs 1.1%; p=0.006) and SBI rupture (11.5% vs 0.2%; p=0.003) was found. Notably a higher rate of SBI rupture without breast cancer in anti-RNAP3+ vs anti-RNAP3- was also noted (2/22 (9.1%) vs 0/514 (0%); p=0.0016).

Conclusion: In this large Italian cohort, a higher prevalence of SBI and SBI rupture in anti-RNAP3+ compared to anti-RNAP3- SSc patients was confirmed, regardless of the history of breast cancer. This preliminary observation should be confirmed in multicentre cohorts, particularly regarding the connection between SSc and SBI rupture.

REFERENCES

Table 1. Frequency of SBI, SBI rupture and breast cancer in SSc 562 SSc patients, divided according to the autoantibody status.

<table>
<thead>
<tr>
<th>Patients</th>
<th>SBI</th>
<th>SBI rupture</th>
<th>Breast cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACA</td>
<td>322</td>
<td>4</td>
<td>16</td>
</tr>
<tr>
<td>Anti-TopoI</td>
<td>125</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>Anti-</td>
<td>26</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>RNAP3</td>
<td>89</td>
<td>2</td>
<td>4</td>
</tr>
<tr>
<td>Others</td>
<td>89</td>
<td>2</td>
<td>4</td>
</tr>
<tr>
<td>Total</td>
<td>562</td>
<td>9</td>
<td>46</td>
</tr>
</tbody>
</table>

Disclosure of Interests: Maria Grazia Lazzaroni: None declared, Cristiano Caimmì: None declared, Eugenia Bertoldo: None declared, Franco Franceschini: None declared, Angela Tincani Consultant for: UCB, Pfizer, Abbvie, BMS, Sanofi, Roche, GSK, AlphaSigma, Lilly, Jannsen, Cellgene, Novartis, Paolo Alì: None declared.


THE EFFECTS OF BOSENTAN FOR TREATMENT OF DIGITAL ULCER IN KOREAN PATIENTS WITH SYSTEMIC SCLEROSIS: PROSPECTIVE, MULTICENTER, OPEN-LABEL TRIAL

Kyuong Ann Lee,1 Hyun-Sook Kim2, Bo Young Kim2, Yun Sung Kim3, Sung Jae Choi,1 Jung Ran Choi.1 1. The Soonchunhyang University Seoul Hospital, Internal Medicine, Seoul, Korea, Rep. of (South Korea); 2. Gangneung Asan Hospital, Internal Medicine, Gangneung, Korea, Rep. of (South Korea); 3. Chosun University Hospital, Internal Medicine, Gwangju, Korea, Rep. of (South Korea);

Background: Bosentan is an orally administered dual endothelin-1 (ET-1) receptor antagonist approved in the EU for reducing the number of new and ongoing digital ulcers in patients with systemic sclerosis (SSc) and ongoing digital ulcer (DU). Oral bosentan therapy was beneficial and generally well tolerated in patients with DU associated with SSc. A total of 3 RCTs were identified. The first two were high quality (RAPIDS-1 and RAPIDS-2) with 122 and 188 patients and treatment durations of 16 and 24 weeks, respectively. Both studies showed that, compared with placebo, bosentan significantly reduced the number of new ulcers; however, it did not have an effect on the healing of preexisting ulcers and pain.

Objectives: This study evaluated the efficacy and safety of bosentan in DU secondary to SSc in Korean patients.

Methods: From December 2013 to December 2017, a prospective, multicenter, open-label trial was performed to investigate the complete healing of DU and tolerability of bosentan in Korean patients with SSc. The SSc...